Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prevalence of Major Depression Among Cancer Patients: Single Center Tertiary Care Hospital Experience from Lahore, Pakistan

Arafat Ali Farooqui, MD, Muhammad Waqas, MD, Aqsa Iftikhar, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5784.

https://doi.org/10.1182/blood-2019-123345

Published: 2019

Journal Articles

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Jordon Jaggers, Heidi D. Klepin, MD, Tanya M. Wildes, MD, Rebecca L. Olin, MD, Andrew S. Artz, MD, Sarah A Wall, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5819.

https://doi.org/10.1182/blood-2019-131504

Published: 2019

Journal Articles

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Gabriele Escherich, Katharina Wos, MD, Franziska Schramm, MD, Martin A. Horstmann, MD

Blood (2018) 132 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2018-99-112623

Published: 2018

Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Nicholas J Short, MD, Maria Khouri, Koichi Takahashi, MD, Maro N. Ohanian, DO, Gautam Borthakur, MD, Marina Y. Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Michelle Velasquez, RN, Patrice Nasnas, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD

Blood (2018) 132 (Supplement 1): 5212.

https://doi.org/10.1182/blood-2018-99-119685

Published: 2018

Journal Articles

Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma

Akanksha Sharma, MD BSc, Natalie Ertz-Archambault, MD, Luke Mountjoy, DO, Alyx Porter, MD, Maciej M Mrugala, MD PhD MPH

Blood (2018) 132 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2018-99-113690

Published: 2018

Journal Articles

Acute Neurotoxicity during ALL Therapy Is Associated with Treatment Intensity, Age and Female Sex - an Analysis of SAE Reports from the UKALL 2003 Trial

Qurat-ul-Ain Wahid, Lina Hamadeh, Sheena McGowan, Rachael Hough, MD BMBS, FRCP, FRCPath, Ajay Vora, MD, Anthony V. Moorman, PhD, Christina Halsey, MD PhD

Blood (2018) 132 (Supplement 1): 1379.

https://doi.org/10.1182/blood-2018-99-113267

Published: 2018

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

Jawed Fareed, PhD, Larissa Reikensmeyer, Amanda Walborn, BS, Debra Hoppensteadt, PhD, Jeanine M. Walenga, PhD, Eduardo Ramacciotti, MD, Schuharazad Abro, MD, Walter Jeske, PhD, Olivia Bouchard, Ismail Elalamy, MD PhD

Blood (2016) 128 (22): 3836.

https://doi.org/10.1182/blood.V128.22.3836.3836

Published: 2016

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis

Aasim S. Sehbai, MBBS, MD, Nouman Asif, MBBS, MD

Blood (2015) 126 (23): 4547.

https://doi.org/10.1182/blood.V126.23.4547.4547

Published: 2015

Journal Articles

Of Mice and Men – or a Lack of Positive Effect of Enhanced Vegetative Nervous System Tonus on Mobilization of Hematopoietic Stem and Progenitor Cells – Results in Patients with Elevated Catecholamine Level in Peripheral Blood Suffering from Acute Psychotic and Anxiety Disorders

Daniel Pedziwiatr, MS, Jolanta Kucharska-Mazur, MD PhD, Ewa Suszynska, MS, Marta Tkacz, MS, Agata Poniewierska, MS, Marta Budkowska, MS, Daria Salata, MS, Barbara Dolegowska, PhD, Jerzy Samochowiec, MD PhD, Mariusz Z Ratajczak, MD PhD

Blood (2014) 124 (21): 2454.

https://doi.org/10.1182/blood.V124.21.2454.2454

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Incidence Of Comorbidities In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Kara Cetin, MPH, Mark Danese, PhD, Aaron J Katz, PharmD, PhD, Michael A Kelsh, PhD, MPH, Michelle Gleeson, PhD, Shilpa S. Alekar, MD, Robert Griffiths, MS, ScD

Blood (2013) 122 (21): 4989.

https://doi.org/10.1182/blood.V122.21.4989.4989

Published: 2013

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1947.

https://doi.org/10.1182/blood.V122.21.1947.1947

Published: 2013

Journal Articles

First-LINE Treatment With High-Dose Dexamethasone Terapy For Adult Primary Inmune Thrombocytopenia

Dana Diaz-Canales, Maria Rosario Prieto-Bonilla, Maria Eva Mingot-Castellano, Ana Isabel Heiniger Mazo

Blood (2013) 122 (21): 1081.

https://doi.org/10.1182/blood.V122.21.1081.1081

Published: 2013

Journal Articles

Encephaloduroarteriosynangiosis (EDAS) For Patients With Sickle Cell Disease

Jeffrey D. Lebensburger, DO, Christina J. Bemrich-Stolz, MD, Christoph Griessenauer, MD, Lee Hilliard, MD, Thomas H. Howard, MD, Michael R. DeBaun, MD, MPH, James M. Johnston, MD

Blood (2013) 122 (21): 999.

https://doi.org/10.1182/blood.V122.21.999.999

Published: 2013

Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 1874.

https://doi.org/10.1182/blood.V118.21.1874.1874

Published: 2011

Journal Articles

Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),

Aziz Nazha, Loretta A Williams, PhD, RN, Hagop M. Kantarjian, Patricia S Ault, MS, ACNP, Araceli Garcia-Gonzalez, MD, PhD, Janet L Williams, MPH, Alexandra Probst, Susan O'Brien, Elias Jabbour, Alfonso Quintas-Cardama, MD, Quiling Shi, MD, PhD, Charles S Cleeland, PhD, Jorge E. Cortes

Blood (2011) 118 (21): 3785.

https://doi.org/10.1182/blood.V118.21.3785.3785

Published: 2011

Journal Articles

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

Tomer M Mark, MD, MSc, Whitney Reid, Ruben Niesvizky, MD, Usama Gergis, MD, Roger N Pearse, MD, PhD, Sebastian Mayer, MD, Morton Coleman, MD, Eric J Feldman, MD, Tsiporah B. Shore, MD

Blood (2011) 118 (21): 2042.

https://doi.org/10.1182/blood.V118.21.2042.2042

Published: 2011

Journal Articles

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Emma C Scott, MD, Alexander Perl, MD, Selina M. Luger, MD, Martin Carroll, MD, Margaret Kasner, MD

Blood (2011) 118 (21): 4245.

https://doi.org/10.1182/blood.V118.21.4245.4245

Published: 2011

NARROW

Prevalence of Major Depression Among Cancer Patients: Single Center Tertiary Care Hospital Experience from Lahore, Pakistan

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease

Psychiatric Disturbance As a Presenting Symptom in Central Nervous Lymphoma

Acute Neurotoxicity during ALL Therapy Is Associated with Treatment Intensity, Age and Female Sex - an Analysis of SAE Reports from the UKALL 2003 Trial

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

De Novo Anemia and Relationship with Vitamin C Deficiency and Zinc Deficiency in a Southern Delaware Population, a Retrospective Analysis

Of Mice and Men – or a Lack of Positive Effect of Enhanced Vegetative Nervous System Tonus on Mobilization of Hematopoietic Stem and Progenitor Cells – Results in Patients with Elevated Catecholamine Level in Peripheral Blood Suffering from Acute Psychotic and Anxiety Disorders

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Incidence Of Comorbidities In Medicare Beneficiaries Diagnosed With Acute Lymphoblastic Leukemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

First-LINE Treatment With High-Dose Dexamethasone Terapy For Adult Primary Inmune Thrombocytopenia

Encephaloduroarteriosynangiosis (EDAS) For Patients With Sickle Cell Disease

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Fatigue in Chronic Myelogenous Leukemia Patients (pts) Treated with Tyrosine Kinase Inhibitors (TKI),

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only